Paradice Investment Management LLC Has $26.67 Million Stock Holdings in Tandem Diabetes Care, Inc. $TNDM

Paradice Investment Management LLC grew its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 24.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,196,468 shares of the medical device company’s stock after purchasing an additional 429,289 shares during the period. Tandem Diabetes Care comprises approximately 6.0% of Paradice Investment Management LLC’s investment portfolio, making the stock its 9th largest position. Paradice Investment Management LLC’s holdings in Tandem Diabetes Care were worth $26,665,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. CWM LLC boosted its position in Tandem Diabetes Care by 262.6% in the second quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock valued at $52,000 after buying an additional 2,025 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company’s stock valued at $78,000 after acquiring an additional 2,717 shares during the last quarter. State of Wyoming boosted its holdings in shares of Tandem Diabetes Care by 49.1% during the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company’s stock valued at $86,000 after acquiring an additional 1,471 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in Tandem Diabetes Care during the 3rd quarter worth $126,000. Finally, Praxis Investment Management Inc. acquired a new position in Tandem Diabetes Care in the 3rd quarter worth about $150,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on TNDM. Morgan Stanley set a $23.00 price target on Tandem Diabetes Care and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Mizuho lifted their target price on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, October 8th. Stifel Nicolaus assumed coverage on shares of Tandem Diabetes Care in a research note on Tuesday, October 21st. They set a “hold” rating and a $15.00 price target for the company. Finally, Baird R W upgraded shares of Tandem Diabetes Care from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $23.94.

Tandem Diabetes Care Stock Down 0.1%

Tandem Diabetes Care stock opened at $22.33 on Tuesday. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -7.32 and a beta of 1.68. Tandem Diabetes Care, Inc. has a 52-week low of $9.98 and a 52-week high of $38.28. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. The firm has a 50 day moving average price of $19.02 and a two-hundred day moving average price of $16.11.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The company had revenue of $249.25 million during the quarter, compared to analysts’ expectations of $235.80 million. During the same period in the prior year, the company posted ($0.35) earnings per share. Tandem Diabetes Care’s revenue for the quarter was up 2.2% compared to the same quarter last year. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.